false
Hamburger Menu
Catalog
2019 IASLC Mesothelioma Meeting
2019 IASLC Mesothelioma Meeting
Conference | English | 2019
Create Account
Availability
On-Demand
15 Courses
Cost
$0.00
Credit Offered
No Credit Offered
Summary
This IASLC meeting is designed to provide information about ongoing clinical trials of the newest therapies for Mesothelioma. The meeting presenters will summarize data on relevant targets for new therapies. Data on preclinical and early clinical data will be presented for each of the drugs directed against these targets. The meeting will also present data on early predictive biomarkers. Additionally, there will be presentations from fellows and young investigators in training and debates about controversial topics. The meeting is a unique resource for clinical investigators, including those in academia, clinical practice and industry.
Release Dates
Live Activity Date: July 10 - 12, 2019
Target Audience
Healthcare professionals who diagnose and treat patients with mesothelioma, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.
Learning Objectives
Upon completion of this activity, the participants should be able to:
For clinical mesothelioma investigators to understand the science behind emerging therapies.
Recognize and plan teh most novel and relevant scientific trials of new therapies.
Program Co-Chairs
Program Co-Chairs:
Michele Carbone, MD, University of Hawaii Cancer Center, Honolulu, HI, USA
Rafael Bueno, MD, Chief Division of Thoracic Surgery, Frederic G. Levin Distinguished Chair of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Harvey Pass, MD, NYU Langone Health, New York, NY, USA
Anne Tsao, MD, Professor, MD Anderson Cancer Center, Houston, TX, USA
Disclaimer
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
If you need assistance with this activity, please email:
education@iaslc.org
.
×
2019 IASLC Mesothelioma Meeting Course List
Keynote Lecture: Malignant Pleural Mesothelioma - Where we have been, Where we are now, and Where we need to go
Immune Checkpoint Inhibitors as Single Agents
Debate 1: PDL1 Tumor Mutation Burden Testing Before Immunotherapy
Radiation
DNA Repair Session
Anti-Metabolites and Chemotherapy
Miscellaneous Session
Debate 2: Genomic Profiling
Mesothelin-Targeting Agents
MET Session
Surgically Resectable Session
Debate 3: Neoadjuvant Chemotherapy vs. No Neoadjuvant Therapy
Immune Checkpoint Inhibitors + Chemo or Other Immune Combination Co-Stimulatory and Co-Inhibitor Molecules
T Cell Therapies
Vaccines and Intrapleural, Gene Therapy
Login
User Login
Continue with Google
OR
Email
Password
Logging In…
Create Account
Forgot Password
×
Please select your language
1
English